## Preliminary Medicare COVID-19 Vaccine Public Use File Methodology

## Overview

The Medicare COVID-19 Vaccine Data Public Use File (PUF) presents information from Medicare Fee-for-Service (FFS) claims for the administration of the COVID-19 vaccine. This PUF provides a high-level and preliminary overview of Medicare utilization and spending from claims that we've received. This PUF does not provide a complete picture of vaccination rates across the Medicare population (please see accompanying documentation 'Assessing the Completeness of Medicare Claims Data for Measuring COVID-19 Vaccine Administration' for estimates of Medicare data completeness).

All data presented in this PUF represent FFS claims with dates of service through 06/30/2023. Due to claims lag, these data may not reflect all COVID-19 vaccine claims that will arrive through that time. This will be the final release of the COVID-19 Vaccine Data PUF due to the end of the Public Health Emergency.

## Methodology

CMS applies suppression to protect the confidentiality of Medicare beneficiaries by avoiding the release of information that can be used to identify individual beneficiaries. Cell values between 1 and 10 are suppressed, and labelled with an asterisk (\*). When necessary, complimentary cells are also suppressed to prevent users from deriving a value between 1 and 10.

**Data Source**: Data are sourced from the Integrated Data Repository (IDR) using final action Medicare FFS claims data and Medicare enrollment information.

Claim Inclusions: Only Medicare beneficiaries enrolled in Part B – either FFS (i.e., Original Medicare) or Medicare Advantage (MA) beneficiaries – are included in this PUF. For dates of service prior to 2022, all claims for the administration of the COVID-19 vaccine were paid through Original Medicare for both FFS and MA beneficiaries. For dates of service on or after January 1, 2022, claims for MA beneficiaries are not included in this report.

**COVID-19 Vaccine Codes**: This file reports utilization and spending data for the administration of the COVID-19 vaccine by vaccine manufacturer, as defined by the following HCPCS codes.

	Pfizer	Moderna	Janssen/Johnson & Johnson	Novavax
Adult	THECT	Wiodeilia	3011113011	Itovavax
First dose	0001A, 0051A	0011A	0031A	0041A
Second dose	0002A, 0052A	0012A		0042A
Third dose/booster	0003A, 0053A, 0004A,		0034A	
	0074A, 0054A, 0073A,	0013A, 0064A,		
	0124A, 0134A, 0173A,	0134A		
	0174A			
Single dose	0121A			
Pediatric				
First dose	0071A, 0081A, 0171A	0091A, 0111A,		
		0141A		
Second dose	0072A, 0082A, 0172A	0092A, 0112A,		
		0142A		
Third dose/booster	0083A, 0154A, 0164A	0093A, 0094A,		
		0113A, 0144A		
Single dose	0151A			

## **Field Definitions**

Claims Received By Date: The latest date for which claims are available in the IDR.

Year/Month of Service: The year and month based on the date of service on the claim.

State of Beneficiary: The state of the beneficiary based on the beneficiary's mailing address.

Claims: A count of claims for the administration of the COVID-19 vaccine.

Medicare Payments: The sum of actual Medicare payments for the administration of the COVID-19 vaccine.